288 related articles for article (PubMed ID: 21156663)
1. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
2. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
3. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
6. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
Seufert J
Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
[TBL] [Abstract][Full Text] [Related]
7. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
8. Clinical decisions. Management of type 2 diabetes.
Goldberg RB; Holman R; Drucker DJ
N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
[No Abstract] [Full Text] [Related]
9. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
Dailey G
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
[TBL] [Abstract][Full Text] [Related]
10. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
11. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
13. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
14. Diabetes medications and body weight.
Mitri J; Hamdy O
Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
16. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
18. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
19. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
ValerĂ³n PF; de Pablos-Velasco PL
Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
[TBL] [Abstract][Full Text] [Related]
20. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]